ICON Plc Aktie News

According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (ICLR 0.92%) by selling 16,096 shares. The transaction was valued at $2.58 million.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the company's leadership position in the clinical research industry, cutting-edge innovation, its efforts in inclusion and sustainability, and as an employer of choice. Acknowledgin...

The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to repurchase $750 million of its outstanding common shares.

DUBLIN--(BUSINESS WIRE)--ICON plc Schedules Second Quarter 2025 Earnings Conference Call.

LOS ANGELES , June 2, 2025 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against ICON Public Limited Company ("ICON" or "the Company") (NASDAQ: ICLR) for violations of the federal securities laws. Shareholders who purchased the Company's securities between July 27, 2023 and October 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm befo...

DUBLIN--(BUSINESS WIRE)--ICON plc to Present at the William Blair 45th Annual Growth Stock Conference.

DUBLIN--(BUSINESS WIRE)--ICON releases its ICON Cares 2024 Report.

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that ...